Premature ovarian failure after childhood cancer and risk of metabolic syndrome: a cross-sectional analysis.
Absorptiometry, Photon
Adipose Tissue
Adult
Anti-Mullerian Hormone
/ blood
Antineoplastic Agents
/ therapeutic use
Antineoplastic Agents, Alkylating
/ therapeutic use
Blood Glucose
/ metabolism
Body Composition
Cancer Survivors
Case-Control Studies
Cholesterol
/ blood
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Female
Glycated Hemoglobin
/ metabolism
Humans
Insulin
/ blood
Metabolic Syndrome
/ epidemiology
Middle Aged
Neoplasms
/ therapy
Primary Ovarian Insufficiency
/ epidemiology
Radiotherapy
/ methods
Risk Factors
Triglycerides
/ blood
Young Adult
Journal
European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848
Informations de publication
Date de publication:
21 May 2021
21 May 2021
Historique:
received:
04
11
2020
accepted:
29
04
2021
pubmed:
30
4
2021
medline:
1
6
2021
entrez:
29
4
2021
Statut:
epublish
Résumé
Female childhood cancer survivors (CCS) are at risk of several late effects, such as metabolic syndrome (MetS) and premature ovarian insufficiency (POI). The objective is to study if POI is associated with risk of MetS and increased cardiovascular risk in CSS. A cross-sectional study with a median time since the cancer diagnosis of 25 (12-41) years. Patients and controls were recruited from the South Medical Region of Sweden. The study included 167 female CCS, median age 34 (19-57) years, diagnosed with childhood cancer at median age 8.4 (0.1-17.9) years together with 164 controls, matched for age, sex, ethnicity, residence, and smoking habits. All subjects were examined with fasting glucose, insulin, HbA1c, and lipid profile. Fat mass was calculated with dual-energy X-ray absorptiometry (DXA), and questionnaires for medication were obtained. Detailed information of cancer treatment was available. POI was present in 13% (22/167) among CCS (hypothalamic/pituitary cause excluded) and in none among controls. MetS was present in 14% (24/167) among all CCS (P = 0.001), in 23% (5/22) of those with POI (P < 0.001), compared with 4% (6/164) among controls. OR for MetS in all CCS compared with controls was 4.4 (95% CI: 1.8, 11.1) (P = 0.002) and among CCS with POI the OR was 7.7 (CI: 2.1, 28.1) (P = 0.002). The prevalence of MetS was higher in females treated for childhood cancer compared with controls, and the presence of POI significantly increased the risk of developing MetS.
Identifiants
pubmed: 33914702
doi: 10.1530/EJE-20-1275
pii: EJE-20-1275
doi:
pii:
Substances chimiques
Antineoplastic Agents
0
Antineoplastic Agents, Alkylating
0
Blood Glucose
0
Cholesterol, HDL
0
Cholesterol, LDL
0
Glycated Hemoglobin A
0
Insulin
0
Triglycerides
0
hemoglobin A1c protein, human
0
Anti-Mullerian Hormone
80497-65-0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM